Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
88,079
result(s) for
"Weight loss."
Sort by:
The personalized diet : the pioneering program to lose weight and prevent disease
\"Helps readers understand the ... science behind [the authors'] work, gives them the tools to create an individualized diet and lifestyle plan (based on their reactions to favorite foods), and puts them on the path to losing weight, feeling good, and preventing disease by eating in the way that's right for them\"-- Provided by publisher.
Book
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
In a phase 3a randomized trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant body-weight reduction in adults without diabetes and with overweight or obesity.
Journal Article
How not to diet : the groundbreaking science of healthy, permanent weight loss
\"[This book] goes beyond food to identify twenty-one weight-loss accelerators available to our bodies, incorporating the latest discoveries in cutting-edge areas like chronobiology to reveal the factors that maximize our natural fat-burning capabilities. [The author] builds the ultimate weight loss guide from the ground up, taking a timeless, proactive approach that can stand up to any new trend. Chock full of actionable advice and groundbreaking dietary research, [this book aims to] put an end to dieting--and replace those constant weight-loss struggles with a simple, healthy, sustainable lifestyle\"--Provided by publisher.
Book
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI). In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years. At 208 weeks, semaglutide was associated with mean reduction in weight (−10.2%), waist circumference (−7.7 cm) and waist-to-height ratio (−6.9%) versus placebo (−1.5%, −1.3 cm and −1.0%, respectively;
P
< 0.0001 for all comparisons versus placebo). Clinically meaningful weight loss occurred in both sexes and all races, body sizes and regions. Semaglutide was associated with fewer serious adverse events. For each BMI category (<30, 30 to <35, 35 to <40 and ≥40 kg m
−
2
) there were lower rates (events per 100 years of observation) of serious adverse events with semaglutide (43.23, 43.54, 51.07 and 47.06 for semaglutide and 50.48, 49.66, 52.73 and 60.85 for placebo). Semaglutide was associated with increased rates of trial product discontinuation. Discontinuations increased as BMI class decreased. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss and improvements in anthropometric measurements versus placebo. Weight loss was sustained over 4 years. ClinicalTrials.gov identifier:
NCT03574597
.
A prespecified analysis of the SELECT trial revealed that patients assigned to once-weekly subcutaneous semaglutide 2.4 mg lost significantly more weight than those receiving placebo and showed improvements in various anthropometric indices.
Journal Article
Magic pill
\"The bestselling author of Lost Connections and Stolen Focus offers a revelatory look at the new drugs transforming weight loss as we know it-from his personal experience on Ozempic to our ability to heal our society's dysfunctional relationship with food, weight, and our bodies\"-- Provided by publisher.
Book
Once-Weekly Semaglutide in Adolescents with Obesity
A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist, is used to treat obesity in adults, but assessment of the drug in adolescents has been lacking.
In this double-blind, parallel-group, randomized, placebo-controlled trial, we enrolled adolescents (12 to <18 years of age) with obesity (a body-mass index [BMI] in the 95th percentile or higher) or with overweight (a BMI in the 85th percentile or higher) and at least one weight-related coexisting condition. Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo for 68 weeks, plus lifestyle intervention. The primary end point was the percentage change in BMI from baseline to week 68; the secondary confirmatory end point was weight loss of at least 5% at week 68.
A total of 201 participants underwent randomization, and 180 (90%) completed treatment. All but one of the participants had obesity. The mean change in BMI from baseline to week 68 was -16.1% with semaglutide and 0.6% with placebo (estimated difference, -16.7 percentage points; 95% confidence interval [CI], -20.3 to -13.2; P<0.001). At week 68, a total of 95 of 131 participants (73%) in the semaglutide group had weight loss of 5% or more, as compared with 11 of 62 participants (18%) in the placebo group (estimated odds ratio, 14.0; 95% CI, 6.3 to 31.0; P<0.001). Reductions in body weight and improvement with respect to cardiometabolic risk factors (waist circumference and levels of glycated hemoglobin, lipids [except high-density lipoprotein cholesterol], and alanine aminotransferase) were greater with semaglutide than with placebo. The incidence of gastrointestinal adverse events was greater with semaglutide than with placebo (62% vs. 42%). Five participants (4%) in the semaglutide group and no participants in the placebo group had cholelithiasis. Serious adverse events were reported in 15 of 133 participants (11%) in the semaglutide group and in 6 of 67 participants (9%) in the placebo group.
Among adolescents with obesity, once-weekly treatment with a 2.4-mg dose of semaglutide plus lifestyle intervention resulted in a greater reduction in BMI than lifestyle intervention alone. (Funded by Novo Nordisk; STEP TEENS ClinicalTrials.gov number, NCT04102189.).
Journal Article
The shred diet cookbook
\"[An] answer to the question Dr. Ian is asked most often: 'Can I eat that on SHRED?' ... He's including nutritionally dense food to match up with the core tenets of meal spacing, meal replacement, and snacking ... Readers get more ideas for snacks than they'll know what to do with; over 75 all-new recipes for meal replacing smoothies and soups, including savory smoothies, warm smoothies, stews, and cold soups; protein-rich dinners ... side-dishes; carb recipes that really count, including breakfast, potatoes, and pastas; some reader-sourced recipes, Southern specialties, and recipes from Ian's family; what to buy; how to work a supermarket; a spice and seasoning primer; alternates for frying, breading and saucing; and much more\"-- Provided by publisher.
Book
Once-Weekly Semaglutide in Adults with Overweight or Obesity
This double-blind study randomly assigned adults with obesity (or overweight and with one or more weight-related coexisting conditions) without diabetes to 68 weeks of once-weekly subcutaneous semaglutide (2.4 mg) or placebo, plus lifestyle intervention. Semaglutide therapy was associated with sustained, clinically relevant weight reduction.
Journal Article
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design
Cardiovascular disease (CVD) is a major cause of morbidity and mortality. Although it has been widely appreciated that obesity is a major risk factor for CVD, treatments that produce effective, durable weight loss and the impact of weight reduction in reducing cardiovascular risk have been elusive. Instead, progress in CVD risk reduction has been achieved through medications indicated for controlling lipids, hyperglycemia, blood pressure, heart failure, inflammation, and/or thrombosis. Obesity has been implicated as promoting all these issues, suggesting that sustained, effective weight loss may have independent cardiovascular benefit. GLP-1 receptor agonists (RAs) reduce weight, improve glycemia, decrease cardiovascular events in those with diabetes, and may have additional cardioprotective effects. The GLP-1 RA semaglutide is in phase 3 studies as a medication for obesity treatment at a dose of 2.4 mg subcutaneously (s.c.) once weekly. Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) is a randomized, double-blind, parallel-group trial testing if semaglutide 2.4 mg subcutaneously once weekly is superior to placebo when added to standard of care for preventing major adverse cardiovascular events in patients with established CVD and overweight or obesity but without diabetes. SELECT is the first cardiovascular outcomes trial to evaluate superiority in major adverse cardiovascular events reduction for an antiobesity medication in such a population. As such, SELECT has the potential for advancing new approaches to CVD risk reduction while targeting obesity.
Journal Article